Overview

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Cancer Prevention Research Institute of Texas
Treatments:
Chlorpromazine
Haloperidol
Haloperidol decanoate
Valproic Acid